|
Variable
|
Number of patients (n = 71)
|
|---|
|
Age at diagnosis (years)
|
|
Median (Range)
|
55 (21–80)
|
|
Gender
| |
|
Male
|
40 (56.3%)
|
|
Female
|
31 (43.7%)
|
|
AJCC stage at diagnosis
|
|
I
|
5 (7.1%)
|
|
II
|
26 (36.6%)
|
|
III
|
40 (56.3%)
|
|
Primary TILs
| |
|
Absent
|
16 (22.6%)
|
|
Present
|
52 (73.2%)
|
|
Non-brisk
|
29
|
|
Brisk
|
23
|
|
Unclassified
|
3 (4.2%)
|
|
Immunotherapy setting
a
| |
|
Adjuvant
|
40 (56.3%)
|
|
At Recurrence
|
31 (43.7%)
|
|
Type of immunotherapy
|
|
Immune biologic
|
38 (53.5%)
|
|
IFN-α
|
21
|
|
IL-2, IL-18
|
4
|
|
GM-CSF
|
12
|
|
Other
|
1
|
|
Vaccine
|
33 (46.5%)
|
|
Dendritic cell
|
11
|
|
Peptide
|
22
|
-
Abbreviations: AJCC American joint committee on cancer, TILs Tumor-infiltrating lymphocytes, NOS Not otherwise specified.
-
aPatients who received immunotherapy in both settings (n=6).
